The biotech company BrainStorm is seeking regulatory approval from the FDA for its cell therapy, NurOwn, which has been developed for the treatment of ALS.

As cancer treatments continue to develop, bispecific cell engagers are revolutionising this therapeutic landscape.

On-Demand Workshop presented by Andreas Castan, Strategic Technologies Director at Cytiva, Cauroline Hausner, Business Development Manager, Aseptic Filling at Cytiva, Ola Tuvesson, Chief Technology Officer at NorthX Biologics & Sofie Östemar, Product Manager, Connected & Continuous at Cytiva

The EU's Clinical Trials Regulation has replaced the union's former Clinical Trials Directive, introducing a centralised application process which aims to ensure consistent timelines for clinical trial reviews.

Xentria and Meitheal partner to develop a breakthrough drug for pulmonary sarcoidosis, aiming to improve patient outcomes.

Given the widespread incidence of cancers and cardiovascular diseases, having sufficient means to model their behaviour is vital to the development of new treatments. Maintaining tissue contexts in disease modelling is crucial for developing a comprehensive understanding of how different diseases behave.

An international European consortium has received a €2.7m grant to improve the safety and effectiveness of CAR-T cell therapies for solid tumours. If successful, the grant could massively improve treatment outcomes for patients.

Examples of Fibonacci spirals in nature include monkey puzzle trees, the double helix of human DNA, and even certain atmospheric patterns. Now, a new study from the University of Edinburgh suggests that the presence of these patterns in early plants may not be as ubiquitous as previously thought.

The collaboration aims to expand access to immunotherapies and advance the field of CAR T cell therapy.

Despite facing criticism in his time, his work laid the foundation for modern immuno-oncology and his legacy continues through the Cancer Research Institute.

We take a look at the work of Sir Gregory Winter, and how it has changed the landscape of therapeutic antibody production.